サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：血栓管理デバイスの世界市場-2023年～2030年
市場調査レポート
商品コード
1352134

血栓管理デバイスの世界市場-2023年～2030年

Global Clot Management Devices Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 186 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
血栓管理デバイスの世界市場-2023年～2030年
出版日: 2023年09月27日
発行: DataM Intelligence
ページ情報: 英文 186 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

血栓管理デバイスは、血栓に関連する問題の予防、特定、治療を目的としています。深部静脈血栓症（DVT）、肺塞栓症（PE）、および動脈血栓症は、これらの機器が治療に使用される疾患の一つです。動脈の血栓は、血栓除去装置を用いて機械的に除去されます。これらの器具は、脚、肺、脳などの体の部位に適用することができます。機械的血栓除去器具と吸引カテーテルはその2つの例です。

カテーテル指向性カテーテルは血栓溶解装置で使用され、血栓に直接血栓溶解薬を送り込みます。これらの薬剤は血栓を溶解し、血流を再開させるのに役立ちます。DVT、PE、その他の疾患はカテーテル直接血栓溶解療法で治療されることが多いです。動脈血栓症、肺塞栓症、深部静脈血栓症などの血管疾患の有病率は増加傾向にあり、血栓管理デバイスの需要を押し上げています。

より効率的で低侵襲な血栓管理ツールの開発は、医療技術の継続的な発展によって可能となり、患者の転帰を改善し、回復を早めています。

ダイナミクス

FDAの承認

例えば、2023年1月、最先端医薬品に特化した世界的な医療企業であるPenumbra, Inc.は、市場で最も洗練された強力な機械的血栓除去システムであるライトニングフラッシュが米国食品医薬品局（FDA）により使用が承認されたと報告しました。ライトニング・フラッシュは、ペナンブラ社の革新的なライトニング・インテリジェント吸引技術とツイン血栓検出アルゴリズムを搭載しています。ライトニングフラッシュは、最先端のカテーテル工学と連携して、静脈血栓や肺塞栓（PE）などの大きな血栓を体内から迅速に除去することを目的としています。

Penumbra ENGINEを搭載したLightning Flashは、圧力と血流に基づくアルゴリズムを用いて血栓と血流を識別します。ライトニングフラッシュカテーテルに使用されているMaxIDハイポチューブ技術により、大口径カテーテルに匹敵する内径を実現しながらも、高さを低く抑え、柔らかく無外傷な先端部は、複雑で繊細な体内構造を通過する際の助けとなります。このカテーテルを併用することで、出血を抑えながら血栓を素早く除去することができます。

積極的な主要企業

2023年3月、インド国内の一部地域において、SMT社はPenumbra社の末梢・冠動脈血栓除去技術の唯一の販売代理店に選ばれたと発表しました。契約に基づき、SMTは、冠動脈血栓症、静脈血栓症、動脈血栓症、肺塞栓症などを治療するために、最近インドの中央医薬品標準管理機構から承認を受けたCATTM RXやLightning技術を含むPenumbra社の最新のIndigoシステムポートフォリオを、規制当局の承認が得られ次第、ヘルスケアプロバイダーに提供します。

ライトニング吸引チューブにより、ペナンブラのインディゴ・システム・ポートフォリオは、血栓と血液を区別し、出血を減らすことができる、最初で唯一のコンピューター支援による機械的吸引技術です。肺塞栓症の治療を含め、末梢動脈系および静脈系の血栓除去を1回で行うために設計されています。さらに、Penumbra社のIndigoシステムCAT RXは、冠動脈や末梢動脈から血栓を安全かつ効果的に除去するために作られています。

主要企業間の協力関係の増加

2023年6月、スマート医療機器分野のリーダーであるセンソームと、ガイドワイヤー業界の世界的リーダーである朝日インテックは、次世代のクロチルド・スマート・ガイドワイヤーを開発するために提携しました。朝日インテックは、急性虚血性脳卒中治療用のこの画期的なデバイスの製造を担当します。

後天的な長期障害の最も一般的な原因は脳虚血性脳卒中であり、この脳虚血性脳卒中は機械的血栓除去術と呼ばれる治療法で治療可能です。この手技は、手首や鼠径部からワイヤーに沿って閉塞部位に誘導する血栓除去器具を使用し、脳の動脈に詰まった血栓を除去するものです。わずかな労力で迅速に血栓を除去することで、患者の予後は大幅に改善します。

心血管疾患の有病率の増加

世界保健機関（WHO）によると、年間1,790万人が死亡しており、心血管疾患（CVD）は世界の死亡原因の第1位です。冠動脈性心疾患、脳血管疾患、リウマチ性心疾患、その他の疾患は、CVDとして知られる心臓や血管の疾患のカテゴリーに含まれます。CVDによる死亡者の5人に4人以上が心臓発作と脳卒中であり、その3分の1が70歳までに死亡しています。

Journal of the American College of Cardiology誌に発表された研究によると、米国では2060年までに心血管系の危険因子と疾患の推定割合が大幅に上昇します。心血管系の動向の大幅な上昇は、アメリカのヘルスケアシステムに大きな負担をかける可能性があり、教育や治療を含む早期疾病予防サービスへの公平なアクセスの必要性を強調しています。

高額のデバイス

新しい医療機器の開発には、綿密なエンジニアリング、調査、臨床試験のすべてが必要であり、これらはすべて、製品を市場に送り出すための全体的な価格に上乗せされます。製造業者は、安全性と有効性に関する厳しい規制基準を遵守するために、徹底的な試験と事務処理に費用をかけなければならず、これがコストを引き上げています。

医療機器には、無菌性、耐久性、生体適合性などの厳しい要件を満たす特殊な材料が頻繁に必要とされます。これらの材料を入手し、加工するコストは高くつく。最先端技術を駆使した複雑な医療機器を製造するには、複雑な製造手順、訓練を受けた人材、品質管理手順が必要になることもあります。

技術的課題

複雑な設計や機能を持つ医療機器を製造する場合、すべての部品が適切に機能することを保証する上で技術的な困難が生じることがあります。特に、成熟したインフラに新しい医療機器を組み込む場合、現在の医療機器、診療行為、ワークフローとの互換性を確保するのは困難な場合があります。

医療機器を安全かつ効果的に使用するためには、ヘルスケア従事者にとって使いやすく、直感的なインターフェースを設計する必要があります。複雑な循環系をカテーテルでナビゲートしながら、周辺組織への傷害を抑えなければならず、そのためには専門知識とハイテク画像ガイダンスが必要となります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • FDAの承認
      • 積極的な主要企業
      • 主要企業間の協力関係の増加
      • 心血管疾患の有病率の増加
    • 抑制要因
      • 高額のデバイス
      • 技術的課題
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • ロシア・ウクライナ戦争の影響分析
  • DMIの見解

第6章 COVID-19分析

第7章 製品別

  • 塞栓バルーンカテーテル
  • カテーテル直接血栓溶解装置
  • 経皮的血栓除去装置
  • 下大静脈フィルター
  • 神経血管塞栓用デバイス
  • その他

第8章 エンドユーザー別

  • 商業・インフラ用
  • 住宅用
  • 産業用

第9章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第10章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第11章 企業プロファイル

  • Medtronic Plc
    • 企業概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な動向
  • Boston Scientific Corporation
  • Edward Lifesciences
  • Teleflex Incorporated
  • Johnson & Johnson
  • LeMaitre Vascular, Inc.
  • AngioDynamics
  • iVascular SLU
  • Cardinal Health
  • Stryker

第12章 付録

目次
Product Code: MD6890

Overview

Clot management devices are intended to prevent, identify, and treat problems linked to blood clots. Deep vein thrombosis (DVT), pulmonary embolism (PE), and arterial thrombosis are among the disorders that these devices are used to treat. Blood clots in blood arteries are mechanically removed using thrombectomy devices. These tools can be applied to the legs, lungs, and brain, among other body areas. Mechanical thrombectomy tools and aspiration catheters are two examples.

Catheter-Directed Catheters are used in thrombolysis devices to deliver thrombolytic drugs directly to the clot. These drugs aid in dissolving the clot and resuming blood flow. DVT, PE, and other diseases are frequently treated with catheter-directed thrombolysis. The prevalence of vascular diseases such as arterial thrombosis, pulmonary embolism, and deep vein thrombosis is on the rise, which has boosted the demand for clot management devices.

The development of more efficient and minimally invasive clot management tools has been made possible by ongoing developments in medical technology, improving patient outcomes and speeding up recovery.

Dynamics

FDA Approvals

For instance, in January 2023, Penumbra, Inc., a worldwide healthcare firm focused on cutting-edge medicines reported that the most sophisticated and potent mechanical thrombectomy system on the market, Lightning Flash, has been approved for use by the U.S. Food and Drug Administration (FDA). Penumbra's innovative Lightning Intelligent Aspiration technology with twin clot detection algorithms, is featured in Lightning Flash. Lightning Flash is intended to quickly remove big blood clots from the body, such as venous thrombus and pulmonary emboli (PE), in conjunction with cutting-edge catheter engineering.

The Penumbra ENGINE-powered Lightning Flash uses pressure- and flow-based algorithms to identify blood clots and blood flow. The MaxID hypotube technology used to create the Lightning Flash catheter allows for an inner diameter that is comparable to large-bore catheters while keeping a low profile and a soft, atraumatic tip intended to aid in navigating the intricate and delicate structure of the body. The device's combined use is meant to facilitate fast blood clot removal while limiting potential blood loss.

Active Major Players

In March 2023, in some domestic Indian regions, SMT stated that it had been chosen as the sole distributor of Penumbra's peripheral and coronary vascular thrombectomy technology. In accordance with the terms of the contract, SMT will offer healthcare providers Penumbra's most recent Indigo System portfolio, including CATTM RX, which recently received approval from India's Central Drug Standard Control Organization, and Lightning technologies, upon regulatory approval, to treat conditions like coronary thrombosis, venous thrombosis, arterial thrombosis, and pulmonary embolism.

With Lightning Aspiration Tubing, Penumbra's Indigo System portfolio is the first and only computer-aided mechanical aspiration technology that can distinguish between clot and blood, reducing blood loss. It is designed for single-session blood clot removal in peripheral arterial and venous systems, including the treatment of pulmonary embolism. Additionally, Penumbra's Indigo System CAT RX is made to remove blood clots from the coronary and peripheral arteries safely and effectively.

Increasing Collaboration Among Key Players

In June 2023, Sensome, a leader in the field of smart medical devices, and Asahi Intecc, a global leader in the guidewire industry, joined forces to create the next-generation Clotild Smart Guidewire. Asahi Intecc will be responsible for manufacturing this ground-breaking device for the treatment of acute ischemic stroke.

The most common cause of acquired long-term disability is a cerebral ischemic stroke, which is treatable with a treatment called mechanical thrombectomy. This procedure uses a thrombectomy tool that is guided along a wire from the wrist or groin to the blockage site to remove a clot that is clogging a blood artery in the brain. Rapid clot removal with little effort significantly improves patient outcomes.

Increasing Prevalence of Cardiovascular Diseases

According to the World Health Organization, with 17.9 million deaths per year, cardiovascular diseases (CVDs) are the leading cause of death worldwide. Coronary heart disease, cerebrovascular disease, rheumatic heart disease, and other illnesses are among the categories of heart and blood vessel disorders known as CVDs. Heart attacks and strokes account for more than four out of every five CVD deaths, and one-third of these deaths happen before the age of 70.

According to a study that was published in the Journal of the American College of Cardiology, the estimated rates of cardiovascular risk factors and disease will considerably rise in the United States by the year 2060. Significant rises in cardiovascular trends could place a greater strain on the American healthcare system and underscore the need for fair access to early disease preventive services including education and treatment.

High Cost of Devices

In-depth engineering, research, and clinical testing are all necessary for the creation of new medical devices, and they all add to the overall price of bringing a product to market. Manufacturers must spend money on thorough testing and paperwork in order to comply with severe regulatory criteria for safety and efficacy, which raises the cost.

Specialized materials that adhere to strict requirements for sterility, durability, and biocompatibility are frequently needed for medical devices. The cost of obtaining and processing these resources can be high. Complex manufacturing procedures, trained personnel, and quality control procedures may be needed to produce intricate medical devices with cutting-edge technology.

Technical Challenges

Technical difficulties in ensuring that all components perform properly together can arise when creating medical devices with complex designs and functionalities. It can be difficult to ensure compatibility with current medical tools, practices, and workflows, particularly when incorporating new devices into mature infrastructures.

For devices to be used safely and effectively, user-friendly, intuitive interfaces for healthcare workers must be designed. Complex circulatory systems must be navigated with catheters while limiting injury to the surrounding tissues, which calls for expertise and high-tech imaging guidance.

Segment Analysis

The global clot management devices market is segmented based on type, end-user and region.

Catheter Directed Thrombolysis Devices Dominate the Market

Deep vein thrombosis (DVT) or pulmonary embolism are two conditions in which blood clots (thrombi) are clogging blood vessels in the legs. Catheter-directed thrombolysis (CDT) is a medical procedure used to treat both conditions. A small, flexible tube called a catheter is placed into the damaged blood artery. Typically, a small incision is used, and imaging methods like fluoroscopy or ultrasound are used to direct the catheter to the clot's location.

A thrombolytic agent, commonly referred to as a clot-dissolving medicine, is administered directly into the clot through the catheter. By dissolving the fibrin strands holding the clot together, thrombolytics enable the body's clot-dissolving systems to clear the impediment. Depending on the size and location of the clot, the length of time the drug is administered can change. The clot is intended to gradually dissolve, allowing blood flow to return. The remnants of the disintegrated clot may occasionally be naturally removed by blood flow. In other situations, the catheter could be utilized to manually or suctionally remove the clot fragments.

Geographical Penetration

Advanced Healthcare Infrastructure, Increased Cardiovascular Disease

North America has been a dominant force in the global clot management devices market. Pulmonary embolism (PE) is a major cause of illness burden. PE is the third biggest cause of cardiovascular disease-related death in the United States, where it is expected to cause 100,000 fatalities annually.

There is growing evidence that prompt and thorough thrombus removal in deep vein thrombosis leads to better results, such as a lower incidence of post-thrombotic syndrome and incapacitating long-term symptoms. Catheter-directed thrombolysis works well to remove clots quickly, however, treatment comes with a high risk of bleeding. Without the need for systemic or catheter-directed thrombolytic therapy, percutaneous mechanical thrombectomy is a very efficient way to remove clots.

For instance, Edwards Lifesciences Corporation offers the Fogarty graft thrombectomy catheter. AV fistulas for dialysis access and grafts for iliofemoral bypass are two examples of synthetic bypass grafts that are intended to be cleaned of organized thrombus and adhering thrombotic debris. They provide a wider range of diameters than the Fogarty adherent clot catheter, which is useful for a thrombus that is too resistant for an elastomeric balloon.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global clot management devices market. Many healthcare systems reallocated resources to deal with COVID-19 cases at the height of the pandemic. Non-urgent medical operations, such as those involving clot management, were consequently delayed.

The management of COVID-19 patients took over hospitals' and healthcare facilities' attention, which had an impact on the resources available for treating other medical disorders. Patient visits to healthcare facilities for conditions unrelated to COVID-19 decreased because of lockdowns, limits on movement, and patient fears of getting the virus.

Russia-Ukraine War Impact Analysis

Healthcare systems may be under pressure by armed situations that take resources and focus away from treatments involving clot management devices. The violence may interrupt supply lines for medical equipment and supplies, which could influence the accessibility of clot control devices.

Patients' ability to reach medical facilities and receive timely clot management therapies is hampered by the conflict. Elective procedures like clot management interventions are delayed if healthcare facilities prioritize urgent cases over non-urgent ones.

By Type

  • Embolectomy Balloon Catheter
  • Catheter Directed Thrombolysis Devices
  • Percutaneous Thrombectomy Devices
  • Inferior Vena cava Filters
  • Neurovascular Embolectomy Devices
  • Others

By End-users

  • Hospitals
  • Ambulatory Surgical Centers
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • In August 2022, Inari Medical announced a trial for the ClotTriever system to treat iliofemoral deep vein thrombosis (DVT).

Competitive Landscape

The major global players in the market include Medtronic Plc, Boston Scientific Corporation, Edward Lifesciences, Teleflex Incorporated, Johnson & Johnson, LeMaitre Vascular, Inc., AngioDynamics, iVascular SLU, Cardinal Health, and Stryker.

Why Purchase the Report?

  • To visualize the global clot management devices market segmentation based on product, end-users, and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of clot management devices market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global clot management devices market report would provide approximately 61 tables, 58 figures, and 186 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product
  • 3.2. Snippet by End-users
  • 3.3. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. FDA Approval
      • 4.1.1.2. Active Major Players
      • 4.1.1.3. Increasing Collaboration Among Key Players
      • 4.1.1.4. Increasing Prevalence of Cardiovascular Diseases
    • 4.1.2. Restraints
      • 4.1.2.1. High Cost of Devices
      • 4.1.2.2. Technical Challenges
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Russia-Ukraine War Impact Analysis
  • 5.6. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 7.1.2. Market Attractiveness Index, By Product
  • 7.2. Embolectomy Balloon Catheter*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Catheter Directed Thrombolysis Devices
  • 7.4. Percutaneous Thrombectomy Devices
  • 7.5. Inferior Vena cava Filters
  • 7.6. Neurovascular Embolectomy Devices
  • 7.7. Others

8. By End-user

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 8.1.2. Market Attractiveness Index, By End-user
  • 8.2. Commercial and Infrastructure*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Residential
  • 8.4. Industrial

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.5.1. U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1. Germany
      • 9.3.5.2. UK
      • 9.3.5.3. France
      • 9.3.5.4. Italy
      • 9.3.5.5. Spain
      • 9.3.5.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. Brazil
      • 9.4.5.2. Argentina
      • 9.4.5.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Medtronic Plc*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
  • 11.2. Boston Scientific Corporation
  • 11.3. Edward Lifesciences
  • 11.4. Teleflex Incorporated
  • 11.5. Johnson & Johnson
  • 11.6. LeMaitre Vascular, Inc.
  • 11.7. AngioDynamics
  • 11.8. iVascular SLU
  • 11.9. Cardinal Health
  • 11.10. Stryker

LIST NOT EXHAUSTIVE

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us